Patients can die if they take certain previously prescribed beta-blockers during a hematopoietic cell transplant due to suppressed signals from nerves that promote bone marrow regeneration, according to scientists at the Children’s Medical Center Research Institute at UT Southwestern, published in Cancer Discovery, builds upon previous CRI research by analyzing retrospective patient data to correlate beta-blocker use with significantly worse patient outcomes.
Elinzanetant successfully met the primary endpoints of the phase III trial OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with breast cancer or at high risk of developing breast cancer, demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (also known as hot flashes) from baseline to week four and 12 compared to placebo.
